Emerging therapies for malignant glioma

References

• Nicholas MK, Lukas RV, Jafri NF, Faoro L, Salgia R. Epidermal growth factor receptor-mediated signal transduction in the development and treatment of gliomas. Clin. Cancer Res.12(6), 7261–7270 (2006).
   PubMed Web of Science ®Google Scholar
• Kopelovich l, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin as a potential target for cancer chemoprevention. Cancer Epidemiol. Biomarkers Prev.16(7), 1330–1340 (2007).
   PubMed Web of Science ®Google Scholar
• Maehama T. PTEN: its deregulation and tumorigenesis. Biol. Pharm. Bull.30(9), 1624–1627 (2007).
   PubMed Web of Science ®Google Scholar
• Bredel M, Pollack IF, Freund JM, Hanilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery43, 124–131 (1998)
   PubMed Web of Science ®Google Scholar
• Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene26, 5541–5552 (2007).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353, 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Lassman AB, Rossi MR, Raizer JJ et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01–03 and 00–01. Clin. Cancer Res.11, 7841–7850 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97, 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• Paez JG, Janne PA, Lee JC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304, 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ, Bell DW, Sordella R et al. Activating mutationsin the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib. N. Engl. J. Med.350, 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Mellinghoff IK, Cloughesy TF, Mischel PS. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res.13, 378–381 (2007).
   PubMed Web of Science ®Google Scholar
• Ramos TC, Figueredo J, Catala M et al. Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a Phase I/II trial. Cancer Biol. Ther.5, 375–379 (2006).
   PubMed Web of Science ®Google Scholar
• Combs SE, Heeger S, Haselmann R et al. Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT)-Phase I/II trial: study protocol. BMC Cancer6, 133 (2006).
   PubMed Web of Science ®Google Scholar
• Wygoda Z, Kula D, Bierzynska-Macszyn G et al. Use of monoclonal anti-EGFR antibody in the radioimmunotherapy of malignant gliomas in the context of EGFR expression in grade III and IV tumors. Hybridoma25, 125–132 (2006).
   PubMed Web of Science ®Google Scholar
• Emrich JG, Brady LW, Quang TS et al. Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol.25, 541–546 (2002).
   PubMed Web of Science ®Google Scholar
• Quang TS, Brady LW. Radioimmunotherapy as a novel treatment regimen: 125I-labeled monoclonal antibody 425 in the treatment of high grade brain gliomas. Int. J. Radiat. Oncol. Biol. Phys.58, 972–975 (2004).
   PubMed Web of Science ®Google Scholar
• Huang SM, Li J, Harari PM. Monoclonal antibody blockade of the epidermal growth factor receptor in cancer therapy. Cancer Chemother. Biol. Response Modif.19, 339–352 (2001).
   PubMedGoogle Scholar
• Bjornst M, Houghton PJ. The TOR pathway: a target for cancer therapy. Nature Rev.4, 335–348 (2004).
   Google Scholar
• Galanis E, Buckner JC, Maurer MJ et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group study. J. Clin. Oncol.23, 5294–5304 (2005).
   PubMed Web of Science ®Google Scholar
• Chang SM, Wen P, Cloughesy T et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest. New Drugs23, 357–361 (2005).
   PubMed Web of Science ®Google Scholar
• Neshat MS, Mellinghoff IK, Tran C et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA98, 10031–10033 (2001).
   PubMedGoogle Scholar
• Doherty L, Gigas DC, Kesari S et al. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology67, 156–158 (2006).
   PubMed Web of Science ®Google Scholar
• Fan QW, Cheng CK, Nicolaides TP et al. A dual phosphoinositide-3-kinase α/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res.67, 7960–7965 (2007).
   PubMed Web of Science ®Google Scholar
• Panner A, Parsa AT, Pieper RO. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme. Exp. Rev. Anticancer Ther.6(9), 1313–1322 (2006).
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The epigenomics of cancer. Cell128, 683–692 (2007).
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352, 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Hau P, Stupp R, Hegi ME. MGMT methylation status: the advent of stratified therapy in glioblastoma? Dis. Markers.23, 97–104 (2007).
   PubMedGoogle Scholar
• Gensert JM, Baranova OV, Weinstein DE, Ratan RR. CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells. Neurobiol. Dis.26, 671–680 (2007).
   PubMed Web of Science ®Google Scholar
• Kamitani H, Taniura S, Wanatabe K et al. Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced. Neuro-oncology4, 95–101 (2002).
   PubMedGoogle Scholar
• Munster P, Marchion D, Bicaku E et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol.25, 1955–1966 (2007).
   PubMedGoogle Scholar
• Glaser KB. HDAC inhibitors: clinical update and mechanism based potential. Biochem. Pharmacol.74, 659–671 (2007).
   PubMed Web of Science ®Google Scholar
• Hockley E, Richon VM, Woodman B et al. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington’s disease. Proc. Natl. Acad. Sci.100, 2041–2046 (2003).
   PubMedGoogle Scholar
• Entin-Meer M, Yang X, VandenBerg SR et al.In vivo efficacy of novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas. Neuro-oncology9, 82–88 (2007).
   PubMedGoogle Scholar
• Feldkamp MM, Lau N, Roncari L, Guha A. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytes regardless of Ras mutational status. Cancer Res.61, 4425–4431 (2001).
   PubMed Web of Science ®Google Scholar
• Guha A. Ras activation in astrocytomas and neurofibromas. Can. J. Neurol. Sci.25, 267–281 (1998).
   PubMed Web of Science ®Google Scholar
• Feldkamp MM, Lau N, Guha A. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene18, 7514–7526 (1999).
   PubMed Web of Science ®Google Scholar
• Cloughesy TA, Kuhn J, Robins IA et al. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol.23, 6647–6656 (2005).
   PubMed Web of Science ®Google Scholar
• Cloughesy TF, Wen PY, Robins HI et al. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J. Clin. Oncol.24, 3651–3656 (2005).
   Google Scholar
• Fouladi M, Nicholson HS, Zhou T et al. A Phase II study of the farnesyl transferase inhibitor tipifarnib, in children with recurrent or progressive high-grade glioma, medulloblastoma/primitive neuroectodermal tumor, or brainstem glioma: a Children’s Oncology Group Study. Cancer PMID 17932894 (2007) (Epub ahead of print).
   Google Scholar
• Delmas C, Heliez C, Cohen-Jonathan E et al. Farnesyltransferase inhibitor R115777, reverses the resistance of human glioma cell lines to ionizing radiation. Int. J. Cancer100, 43–49 (2002).
   PubMed Web of Science ®Google Scholar
• Cohen-Jonathan E, Laprie A, Delannes M et al. Phase I trial of tipifarnib (R115777) concurrent with radiotherapy in patients with glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.68(5), 1396–1401 (2007).
   PubMedGoogle Scholar
• Folkman J. Targeting angiogenesis: therapeutic implications. N. Engl. J. Med.285(21), 1182–1186 (1971).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Tuettenberg J, Friedel C, Vajkoczy P. Angiogenesis in mammalian glioma–a target for antitumor therapy? Crit. Rev. Oncol. Hematol.59, 181–193 (2006).
   PubMed Web of Science ®Google Scholar
• Criscuolo GR, Merrill ML, Oldfield EH. Further characterization of malignant glioma-derived vascular permeability factor. J. Neurosurg.69(2), 254–262 (1988).
   PubMedGoogle Scholar
• Lennmyr F, Ata KA, Funa K, Olsson Y. Expression of vascular endothelial growth factor (VEGF)and its receptors (Flk-1 and Flt-1) following permanent and transient occlusion of the middle cerebral artery in the rat. J. Neuropathol. Exp. Neurol.57(9), 874–882 (1998).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2336–2342 (2004).
   Google Scholar
• Stark-Vance V. Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Proceedings of the World Federation of Neuro-Oncology 2nd Quadrennial Meeting, Edinburgh, UK 5 May–8 May 2005.
   Google Scholar
• Vredenburgh J, Desjardins A, Herndon II JE et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res.13(4), 1253–1259 (2007).
   PubMed Web of Science ®Google Scholar
• Vredenburgh J, Desjardins A, Herndon II JE et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J. Clin. Oncol.25, 4722–4729 (2007).
   PubMed Web of Science ®Google Scholar
• Conrad H, Friedman H, Reardon D. A I/II trial of single agent PTK787/ZK222584 (PTK/ZK), a novel oral angiogenesis inhibitor in patients with recurrent glioblastoma multiforme (GBM). Proc. Annu. Meet. Am. Soc. Clin. Oncol.22, 1512 (2004).
   Web of Science ®Google Scholar
• Batchelor TT, Sorenson AG, di Tomaso E et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell11, 83–85 (2007).
   PubMed Web of Science ®Google Scholar
• Damiano V, Melisi D, Bianco C et al. Cooperative antitumor effect of multitargeted kinase inhibitor and ionizing radiation in glioblastoma. Clin. Cancer Res.11, 5839–5844 (2005).
   Google Scholar
• Melchert M, List A. The Thalidomide saga. Int. J. Biochem. Cell Biol.39, 1489–1499 (2007).
   PubMed Web of Science ®Google Scholar
• Chang Sm, Lamborn KR, Malec M et al. Phase II study f temozolomide and thalidomide with radiation therapy for newly diagnosed glioblastoma multiforme. Int. J. Radiat. Oncol. Biol. Phys.60, 353–357 (2004).
   PubMed Web of Science ®Google Scholar
• Rabbani G, Benzil D, Wallam MM et al. Combination therapy with thalidomide, temozolomideand tamoxifen improves quality of life in patients with malignant astrocytomas. Anticancer Res.27(4C), 2729–2736 (2007).
   PubMed Web of Science ®Google Scholar
• Riva M, Imbesi F, Beghi E et al. Temozolomide and thalidomide in the treatment of glioblastoma multiforme. Anticancer Res.27(2), 1067–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Taga T, Suzuki A, Gonzalez-Gomez I et al. alpha v-integrin antagonist EMD 121974 induces apoptosis in brain tumor cells growing on vitronectin and renascin. Int. J. Cancer98, 690–697 (2002).
   PubMed Web of Science ®Google Scholar
• Omuro AMP, Faivre S, Raymond E. Lessons learned from the targeted therapy of malignant gliomas. Mol. Cancer Ther.6(7), 1909–1919 (2007).
   PubMed Web of Science ®Google Scholar